Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: Population-based and single-institutional analysis - Abstract

PURPOSE: Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma is unclear.

To assess whether PN provides adequate cancer control in high-risk disease (HRD), survival outcomes were compared in both a population-based cohort and an institutional cohort.

METHODS: Surveillance, Epidemiology, and End Results database and a prospectively maintained institutional database were queried for patients with RCC who underwent PN or RN for a localized tumor ≤ 7 cm and were found to have high-grade and/or high-stage disease (HRD). Cancer-specific (CSS) or recurrence-free survival (RFS) and overall survival (OS) were primary outcomes measured and were compared between those who underwent PN and RN using multivariable Cox proportional hazards and propensity analysis.

RESULTS: The population cohort consisted of 12,757 (24.9 %) patients with HRD, 85.2 and 14.8 % of which underwent RN and PN, respectively. RN was not associated with CSS (HR 1.23, p = 0.08) but was independently associated with poor OS (HR 1.16, p = 0.031). Propensity analysis showed that RN resulted in a 20 % increased risk of death from all causes (p = 0.008). In the institutional cohort, of 317 patients, 35.9 % had HRD, 56 and 52 of which underwent RN and PN, respectively. Adjusting for age-adjusted Charlson index, RN was a predictor of poor OS (OR 6.20, p = 0.041). Propensity analysis showed that RFS and OS were not related to nephrectomy type (RN HR 0.65, p = 0.627 and RN HR 1.70, p = 0.484).

CONCLUSIONS: In patients with pathologic high-risk RCC, partial excision is associated with similar cancer control as compared to radical excision.

Written by:
O'Malley RL, Hayn MH, Brewer KA, Underwood W 3rd, Hellenthal NJ, Kim HL, Sorokin I, Schwaab T.   Are you the author?
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.  

Reference: World J Urol. 2015 Mar 25. Epub ahead of print.
doi: 10.1007/s00345-015-1538-z


PubMed Abstract
PMID: 25805189

UroToday.com Renal Cancer Section